loading page

Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database
  • +1
  • Diogo Mota,
  • Tiago Rama,
  • Milton Severo,
  • André Moreira
Diogo Mota
Centro Hospitalar Universitario de Sao Joao
Author Profile
Tiago Rama
Centro Hospitalar Universitario de Sao Joao
Author Profile
Milton Severo
Universidade do Porto Instituto de Saude Publica
Author Profile
André Moreira
Centro Hospitalar Universitario de Sao Joao
Author Profile

Peer review status:ACCEPTED

28 Jun 2021Submitted to Allergy
29 Jun 2021Assigned to Editor
29 Jun 2021Submission Checks Completed
29 Jun 2021Reviewer(s) Assigned
07 Jul 2021Review(s) Completed, Editorial Evaluation Pending
08 Jul 2021Editorial Decision: Accept